ADHD in women and girls statistics: the late-diagnosis gap in plain numbers

She was 34, two kids, a job she could not keep up with, and a stack of sticky notes that never quite became a system. She had been treated for anxiety since college and for depression after her second pregnancy. Antidepressants blunted the low mood. They did nothing for the missed deadlines, the half-finished tasks, or the way her mind scattered the moment a child needed something. A pediatrician friend finally said, almost offhand, that the pattern sounded less like anxiety alone and more like ADHD that had never been named.

She was right. By the time we sorted it out, she had spent more than a decade in mental health care without anyone screening her for a neurodevelopmental condition that typically begins in childhood. That is not a rare story in women's health. It is one of the more common ones I hear when patients finally bring the right vocabulary in.

The numbers behind that delay are now clearer than they were five years ago. According to NCHS, U.S. girls ages 3 to 17 are ever diagnosed with ADHD at 8.2%, compared with 15.6% of boys. Among adults, a 2023 CDC rapid survey estimated that 15.5 million U.S. adults (6.0%) had a current ADHD diagnosis, and 55.9% of them first received the diagnosis at age 18 or older. This article gathers the primary-source statistics a reporter can quote with confidence: childhood sex gaps, the adult-diagnosis surge, age at identification, presentation differences, stimulant shortages, and comorbidity.

Group	Ever diagnosed with ADHD	Source year
Girls, ages 3-17	8.2%	NHIS 2024 (NCHS FastStats)
Boys, ages 3-17	15.6%	NHIS 2024 (NCHS FastStats)
Girls, ages 5-17	8.0%	NHIS 2020-2022 (NCHS Data Brief 499)
Boys, ages 5-17	14.5%	NHIS 2020-2022 (NCHS Data Brief 499)
Girls, ages 5-11	5.9%	NHIS 2020-2022
Girls, ages 12-17	10.4%	NHIS 2020-2022

Source: National Center for Health Statistics, National Health Interview Survey (FastStats 2024; Data Brief No. 499, 2020-2022 pooled estimates).

Year	Prescriptions dispensed (millions)
2012	21.6
2014	24.9
2016	28.8
2018	29.9
2020	32.8
2021	36.6
2022	40.5

Source: IQVIA Government Solutions, Stimulant Prescription Trends in the United States From 2012-2022 (report prepared for the DEA, August 31, 2023). Female prescriptions rose 87.5% over the decade; women surpassed men in dispensed stimulant prescriptions in 2022.

Girls vs boys: the childhood diagnosis gap

Start with the childhood numbers, because that is where the sex gap is sharpest and easiest to quote.

According to NCHS FastStats based on the 2024 National Health Interview Survey, 12.0% of U.S. children ages 3 to 17 have ever been diagnosed with ADHD. Among boys the figure is 15.6%. Among girls it is 8.2%. That is almost a 2-to-1 ratio in diagnosed prevalence.

The same pattern holds in NCHS Data Brief No. 499 (2020-2022 NHIS): 11.3% of children ages 5 to 17 ever diagnosed. That was 14.5% of boys and 8.0% of girls. The gap is present early and stays present. Among ages 5 to 11, 5.9% of girls and 11.3% of boys had ever received the diagnosis. Among ages 12 to 17, rates rise to 10.4% of girls and 17.9% of boys.

CDC's ADHD data page, drawing on National Survey of Children's Health estimates for 2022-2023, puts the split at 13% of boys versus 7% of girls. A 2024 peer-reviewed analysis of the 2022 NSCH by Danielson and colleagues found that about 1 in 9 U.S. children (11.4%, or 7.1 million) had ever received an ADHD diagnosis, and 10.5% (6.5 million) had current ADHD. CDC later reported an estimated 7 million children (11.7%) with current ADHD in 2024 survey data.

None of these sources claim that true biological prevalence is half as high in girls. They report diagnosed prevalence. Referral pathways still tilt toward hyperactive-impulsive presentations more often noticed in boys. Girls who present primarily with inattention can look quiet, daydreamy, or "anxious" rather than disruptive, and they get referred later, if they get referred at all.

The adult-diagnosis surge among women

Adult ADHD used to rest on an older estimate of about 4.4% current prevalence from the National Comorbidity Survey Replication. That figure still appears on older NIMH summary pages. It is no longer the best national snapshot for the United States.

In October-November 2023, the National Center for Health Statistics Rapid Surveys System asked a nationally weighted sample of U.S. adults about ADHD diagnosis and treatment. The resulting CDC MMWR report estimated that 15.5 million adults (6.0%, or roughly 1 in 16) had a current ADHD diagnosis. Of adults with current ADHD, 44.2% were female and 55.8% were male. The childhood boy-heavy ratio had narrowed substantially by adulthood.

Age at diagnosis is the sentence most reporters need. More than half of adults with ADHD, 55.9%, first received their diagnosis at age 18 or older. Only 44.1% were diagnosed before 18. Diagnostic criteria still require childhood-onset symptoms, but formal labeling often arrives years after the symptoms do. For many women, that label arrives after college or after the scaffolding of school and parental structure falls away.

Treatment access is uneven. In the same 2023 survey, 36.5% of adults with current ADHD reported no ADHD treatment in the previous 12 months. About one third (35.2%) received both medication and counseling or behavioral treatment. Half (50.4%) had been prescribed medication for ADHD in the prior year; 33.4% reported taking a stimulant and 5.9% a nonstimulant. Nearly half (46.0%) had ever used telehealth for ADHD-related care.

Stimulant prescribing data show where growth is concentrated. CDC analysis of MarketScan commercial claims for 2016-2021 found that the share of enrollees with at least one stimulant fill rose from 3.6% to 4.1% overall. Among females, the largest single-year jumps came during 2020-2021. Annual percent changes were 14.3% to 19.2% among females ages 15-44 and 50-54. Female enrollees overall went from 3.2% with a stimulant fill in 2016 to 4.1% in 2021.

A longer series from IQVIA, prepared for the DEA, is sharper still. From 2012 to 2022, stimulant prescriptions dispensed rose 57.9%, from 50.4 million to 79.6 million. Prescriptions to females rose 87.5%, from 21.6 million to 40.5 million, versus 35.3% growth for males. In 2022, for the first time in that series, women received slightly more dispensed stimulant prescriptions than men. That does not prove overdiagnosis. It is also consistent with under-recognition partially correcting itself. Both can be true in different subgroups, and the U.S. still lacks adult ADHD clinical practice guidelines comparable to those for children.

Average age at diagnosis

U.S. national surveys show that adult diagnosis is common. They do not always give a clean mean age of first diagnosis for women versus men. For that, the strongest population-based evidence currently comes from abroad.

Skoglund and colleagues used Swedish national registers. Females were older at ADHD-index: a mean of 23.5 years (SD 13.8) versus 19.6 years (SD 13.9) for males. The difference was about 3.9 years (95% CI 3.74-4.11). In that system, girls and women received the ADHD diagnosis nearly four years later than boys and men.

The delay is not because symptoms appear later. Symptoms typically begin in childhood for both sexes. What differs is recognition. Girls are more often filtered into anxiety or mood pathways first; teachers refer disruptive boys more readily than quiet, disorganized girls. By the time a woman is diagnosed, she may already have a chart full of other psychiatric labels. Some are accurate as comorbidities. Others are partial misreads of untreated ADHD.

U.S. data do not yet publish a single official mean age of ADHD diagnosis in American women. What they give is the adult catch-up signal: 55.9% of currently diagnosed adults were first labeled at 18 or older, and women now make up 44.2% of the adult ADHD population.

Why presentation differs in girls and women

ADHD is not a different disease in females. The same symptom domains apply: inattention and hyperactivity-impulsivity. The mix and visibility differ. So does the social response.

A widely cited clinical review by Quinn and Madhoo in The Primary Care Companion for CNS Disorders (2014) summarizes why girls are missed: lower clinician suspicion, presentations judged "subthreshold" because inattention outruns obvious hyperactivity, better masking or compensatory strategies in some girls, and high rates of anxiety and depression that pull the diagnostic process sideways. Girls with ADHD may look shy, overwhelmed, or "scattered" rather than classically hyperactive. Internal restlessness is harder to code than a boy who cannot stay in his seat.

Hormonal context adds another layer pediatric criteria were not built to capture. Many women report that ADHD symptoms worsen premenstrually, postpartum, or in perimenopause, when estrogen fluctuation can unmask executive-function problems that were previously compensated. The research base here is thinner than the clinical anecdotes, and I will not invent a prevalence percentage the literature does not cleanly support. What is solid is that reproductive transitions are common moments when previously undiagnosed ADHD becomes impossible to ignore.

That pathway intersects with broader mental health patterns. Women already carry higher rates of diagnosed anxiety and depression; see our review of women's mental health statistics on anxiety and depression. When ADHD rides underneath, treating only the mood piece leaves the executive dysfunction intact. Sleep disruption is part of the same tangle: women face elevated insomnia risk across the reproductive lifespan, detailed in our sleep disorders statistics for women, and ADHD often co-travels with delayed sleep.

For patients tracking whether symptoms cluster around their cycle, our period calculator and cycle length calculator can help map timing against menstruation, not as a diagnostic test but as a structured history for specialist evaluation.

Stimulant shortage impact

Recognition is only useful if treatment is available. For a large share of adults with ADHD, it has not been.

The FDA announced a shortage of Adderall (amphetamine mixed salts) in October 2022, citing manufacturing delays that other producers could not fully offset. Multiple stimulant products and strengths then faced intermittent or prolonged unavailability, intersecting with DEA production quotas for Schedule II substances and a sharp rise in demand.

The clearest patient-level impact number comes from the 2023 CDC adult ADHD survey. Among adults who reported taking a stimulant ADHD medication in the previous 12 months, 71.5% said they had difficulty getting their prescription filled because the medication was not available. Among adults taking any ADHD medication, 61.8% reported fill difficulty due to unavailability. That is a majority of treated adults colliding with empty pharmacy shelves.

Demand had already been climbing for a decade. IQVIA's DEA-commissioned analysis found a 57.9% increase in stimulant prescriptions dispensed from 2012 to 2022. Growth was steepest among women and adults ages 31 to 40. That age band more than tripled, from 5.4 million to 17.5 million. The 2020-2021 jump in female fills arrived just as supply was least able to absorb it.

When a medication that organizes working memory and emotional regulation vanishes for weeks, work performance collapses and mood destabilizes. Some patients look for medication outside regulated channels. CDC warned in a 2024 Health Advisory that shortages raise overdose risk because counterfeit pills may contain unexpected substances such as fentanyl. Nonstimulant options exist: atomoxetine, viloxazine, guanfacine, and clonidine. IQVIA found that about 10% of ADHD treatment molecules dispensed in 2022 were nonstimulants. They help some patients but are not interchangeable for everyone who responds best to amphetamine or methylphenidate products.

Comorbidity rates

ADHD rarely travels alone, and the companions differ by sex.

Among U.S. children with current ADHD, Danielson and colleagues found that 77.9% had at least one co-occurring disorder in 2022 NSCH data. The most common were behavioral or conduct problems (44.1%) and anxiety problems (39.1%); depression affected 18.9%. Learning disability was the most common developmental co-occurrence at 36.5%. About 6 in 10 children with ADHD had moderate or severe ADHD. Nearly one third (30.1%) received no ADHD-specific medication or behavioral treatment in the past year. A treatment gap has widened since 2016, when 23% went untreated by those measures.

Adult sex differences are starker in the Swedish register data. Skoglund et al. found that females with ADHD were roughly twice as likely as males with ADHD to have anxiety disorders (50.4% vs. 25.9%) and mood disorders (37.5% vs. 19.5%). Eating disorders showed one of the largest relative gaps: 5.6% of females with ADHD versus 0.6% of males. Personality disorders were also more common in females (6.3% vs. 2.1%). Males with ADHD had higher rates of autism spectrum disorders, conduct disorder, and tic disorders.

Those eating-disorder numbers matter because the conditions can mask each other. A young woman with binge-eating patterns and chaotic meal timing may meet criteria for an eating disorder while underlying ADHD impulsivity goes untreated. Our review of eating disorder statistics in women covers prevalence and treatment gaps. Postpartum is another high-risk window: untreated ADHD can amplify organizational chaos and mood risk, and families navigating patterns in our postpartum depression statistics should not have longstanding ADHD waved away as "new-mom brain."

What the comorbidity data do not support is a clean story that girls simply have "milder" ADHD. They often have a different external presentation and a heavier load of internalizing disorders. Milder in the classroom is not milder in a life.

The practical takeaway is the same for clinicians and reporters. Quote the childhood sex gap, the 55.9% adult first-diagnosis figure, the 71.5% shortage fill-failure rate, and the roughly twofold anxiety and mood burden in females with ADHD. Those numbers describe a system that under-identifies girls, partially catches up in adulthood, then struggles to keep medication available.

The patient who came in at 34 is doing better on stimulant medication, when she can fill it, and structured behavioral supports. She is still angry about the decade she spent thinking she was failing. The statistics say she was never alone. The diagnostic system failed first.

Frequently asked questions about ADHD in women and girls

How common is ADHD in girls compared with boys?

According to NCHS FastStats from the 2024 National Health Interview Survey, 8.2% of U.S. girls ages 3-17 have ever been diagnosed with ADHD, compared with 15.6% of boys. NCHS Data Brief No. 499 (2020-2022) found 8.0% of girls and 14.5% of boys ages 5-17 ever diagnosed. CDC parent-survey estimates for 2022-2023 put the split at about 7% of girls versus 13% of boys.

What share of adults with ADHD are first diagnosed in adulthood?

In the CDC's 2023 NCHS Rapid Surveys System analysis, 55.9% of U.S. adults with a current ADHD diagnosis first received that diagnosis at age 18 or older. An estimated 15.5 million adults (6.0%) had current ADHD. Women made up 44.2% of adults with current ADHD, a much narrower sex gap than in childhood data.

Are women diagnosed with ADHD later than men?

Yes, in large population data. A Swedish national register study by Skoglund and colleagues found females received their ADHD index diagnosis at a mean age of 23.5 years versus 19.6 years for males, nearly a four-year delay, despite symptoms typically beginning in childhood for both sexes. U.S. surveys show adult first diagnosis is common but do not publish a single official mean age by sex.

How has the stimulant shortage affected people with ADHD?

Among U.S. adults taking stimulant ADHD medication in 2023, 71.5% reported difficulty filling a prescription because the medication was unavailable, per CDC MMWR analysis of NCHS data. The FDA announced an Adderall shortage in October 2022. Demand had already risen: IQVIA data show female stimulant prescriptions rose 87.5% from 2012 to 2022.

What mental health conditions commonly occur with ADHD in women?

In the Swedish register study, females with ADHD had anxiety disorders in 50.4% of cases and mood disorders in 37.5%, roughly double the rates in males with ADHD (25.9% and 19.5%). Eating disorders were reported in 5.6% of females with ADHD versus 0.6% of males. Among U.S. children with ADHD overall, 77.9% have at least one co-occurring condition, including anxiety in 39.1%.

Why is ADHD often missed in girls?

Clinical reviews, including Quinn and Madhoo (2014), point to lower clinician suspicion, more inattentive than hyperactive-impulsive presentations, compensatory masking, and high rates of anxiety and depression that can draw attention away from ADHD. Girls are less likely to disrupt a classroom, so they are less likely to be referred early even when impairment is real.